Q-omics provides the consensus-scored GALNT13 profile across patient tissues and cancer cell-line models. GALNT13 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GALNT13 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, GALNT13 RNA expression shows 14,911 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, LUAD, and THYM as cancer lineages where GALNT13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT13 survival associations across molecular data types. GALNT13 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT13 RNA expression–survival associations across cancer types. High GALNT13 expression shows unfavorable associations in STAD, MESO, LUAD, HNSC and UCEC, but favorable associations in LGG. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for GALNT13 RNA expression.
This table summarizes GALNT13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GALNT13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT13 shows lower tumor expression in LUAD, KICH, LUSC and COAD and higher tumor expression in THCA and HNSC. The LUAD box plot shows higher GALNT13 RNA expression in normal versus tumor tissue (log2 FC = −1.796, t-test p < 0.001).
This table shows molecular features associated with GALNT13 in patient tissues and cancer cell lines. In patient samples, GALNT13 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
